Ironwood Pharmaceuticals ... (IRWD)
| Bid | 1.38 |
| Market Cap | 227.24M |
| Revenue (ttm) | 352.12M |
| Net Income (ttm) | 73.19M |
| EPS (ttm) | 0.01 |
| PE Ratio (ttm) | 142 |
| Forward PE | 17.88 |
| Analyst | Buy |
| Ask | 1.42 |
| Volume | 3,179,062 |
| Avg. Volume (20D) | 3,038,689 |
| Open | 1.52 |
| Previous Close | 1.53 |
| Day's Range | 1.37 - 1.55 |
| 52-Week Range | 1.34 - 9.10 |
| Beta | 0.37 |
About IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...
Analyst Forecast
According to 4 analyst ratings, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 604.23% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call TranscriptIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Greg Martini - Chief Financial Officer Tom McCourt - Chief Executive Of...
